Jul 14, 2026 08:00AM
Jul 14, 2026 08:00AM
Jul 1, 2026 04:01PM
Jun 11, 2026 07:03AM
Jun 11, 2026 07:03AM
Jun 11, 2026 07:02AM
Jun 11, 2026 07:00AM Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Cl
Jun 4, 2026 04:01PM
Jun 4, 2026 07:00AM
Jun 4, 2026 07:00AM
Jun 2, 2026 04:01PM
Jun 2, 2026 04:01PM
Jun 1, 2026 07:00AM
Jun 1, 2026 07:00AM Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026
May 21, 2026 05:01PM
May 21, 2026 05:01PM
May 20, 2026 07:00AM
May 12, 2026 10:31AM
May 6, 2026 04:01PM
Apr 30, 2026 04:01PM
Apr 24, 2026 07:00AM Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026
Apr 3, 2026 04:01PM
Mar 4, 2026 04:01PM
Feb 26, 2026 04:01PM
Feb 23, 2026 07:00AM
Feb 19, 2026 07:00AM
Feb 5, 2026 07:00AM
Feb 4, 2026 04:01PM Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jan 12, 2026 07:08AM
Jan 12, 2026 07:00AM
Jan 7, 2026 07:00AM
Jan 5, 2026 07:00AM
Dec 12, 2025 07:00AM
Dec 9, 2025 04:34AM
Dec 8, 2025 06:50AM Syndax presents real-world data for menin inhibitor at ASH conference
Dec 8, 2025 06:50AM
Dec 3, 2025 04:01PM
Dec 1, 2025 07:00AM
Nov 5, 2025 04:01PM
Nov 3, 2025 04:01PM
Nov 3, 2025 09:09AM
Nov 3, 2025 09:08AM Syndax Announces Compelling Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Data Accepted for Presentation at ASH 2025
Nov 3, 2025 09:08AM
Oct 30, 2025 07:00AM
Oct 27, 2025 07:48AM
Oct 27, 2025 07:00AM
Oct 24, 2025 01:59PM
Oct 24, 2025 01:58PM
Oct 24, 2025 01:08PM FDA approves Syndax Pharmaceuticals' (SNDX) revumenib for myeloid leukemia
Oct 3, 2025 04:01PM

326,536 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All